USFDA pulls up Smruthi Organics for norms violation in unit

PTI New Delhi | Updated on October 21, 2013 Published on October 21, 2013

Smruthi Organics today said it has received a notification from the USFDA highlighting violations of manufacturing norms at its Solapur plant, in yet another instance of an Indian drug maker failing to comply with norms of the US health regulator.

In a filing to the BSE, the company said the European Directorate for Quality of Medicines (EDQM) and the US Food and Drug Administration (USFDA) have inspected its active pharmaceutical ingredients site from October 14-18, 2013.

“USFDA has issued their observations in form 483. EDQM is yet to submit its final inspections report,” Smruthi Organics Ltd added.

It, however, did not specify the shortcomings found by the USFDA inspectors at its plant.

“After the resolution of the observations to the satisfaction of the regulators, the company will be able to resume supplies of its products to the EU and US markets,” Smruthi Organics said.

A USFDA Form 483 is issued to a firm after completion of an inspection when its investigator(s) observe any conditions that may constitute violations of the Food Drug and Cosmetic (FD&C) Act and related Acts, notifying the objectionable conditions.

India’s drug majors Ranbaxy Laboratories and Wockhardt have been in the news after their different plants were found to be violating the current good manufacturing norms of the USFDA.

Ranbaxy has agreed to pay a $500-million penalty to US authorities after its plants at Paonta Sahib and Dewas were found to be violating norms. USFDA has also recently banned import of drugs made at its Mohali plant.

Wockhardt is also trying to resolve issues after its plants at Waluj and Chikalthana were found not adhering to norms specified by the USFDA.

Published on October 21, 2013

A letter from the Editor

Dear Readers,

The coronavirus crisis has changed the world completely in the last few months. All of us have been locked into our homes, economic activity has come to a near standstill. Everyone has been impacted.

Including your favourite business and financial newspaper. Our printing and distribution chains have been severely disrupted across the country, leaving readers without access to newspapers. Newspaper delivery agents have also been unable to service their customers because of multiple restrictions.

In these difficult times, we, at BusinessLine have been working continuously every day so that you are informed about all the developments – whether on the pandemic, on policy responses, or the impact on the world of business and finance. Our team has been working round the clock to keep track of developments so that you – the reader – gets accurate information and actionable insights so that you can protect your jobs, businesses, finances and investments.

We are trying our best to ensure the newspaper reaches your hands every day. We have also ensured that even if your paper is not delivered, you can access BusinessLine in the e-paper format – just as it appears in print. Our website and apps too, are updated every minute, so that you can access the information you want anywhere, anytime.

But all this comes at a heavy cost. As you are aware, the lockdowns have wiped out almost all our entire revenue stream. Sustaining our quality journalism has become extremely challenging. That we have managed so far is thanks to your support. I thank all our subscribers – print and digital – for your support.

I appeal to all or readers to help us navigate these challenging times and help sustain one of the truly independent and credible voices in the world of Indian journalism. Doing so is easy. You can help us enormously simply by subscribing to our digital or e-paper editions. We offer several affordable subscription plans for our website, which includes Portfolio, our investment advisory section that offers rich investment advice from our highly qualified, in-house Research Bureau, the only such team in the Indian newspaper industry.

A little help from you can make a huge difference to the cause of quality journalism!

Support Quality Journalism
This article is closed for comments.
Please Email the Editor
You have read 1 out of 3 free articles for this week. For full access, please subscribe and get unlimited access to all sections.